From September, Dr Baselga combines the scientific management of the Vall d’Hebron Institute of Oncology (VHIO) with his new appointment at the Hematology & Medical Oncology Division at the Cancer Center of the Massachusetts General Hospital at Harvard Medical School in Boston.
Related Posts
VHIO and the Fritz Bender Foundation present latest advances in individualized cancer treatments
17th Fritz Bender Foundation International Symposium: Progress Towards Individualized Cancer Treatments, 07 – 09 November, 2013 To be inaugurated today,…
12 Nov 2013
Molecular Oncology News and Views: VHIO-Fritz Bender Foundation International Symposium on Progress Towards Individualized Cancer Treatments, 07 – 09 November 2013
Molecular Oncology 8 (2014) 1-8 News and views Towards individualized cancer therapy: Challenges and prospects Ezzie Hutchinson ABSTRACT At the…
14 Feb 2014
Oncology channel ecancerTV catches up in Chicago with VHIO´s Rodrigo Dienstmann and Enriqueta Felip
During this year´s Annual Meeting of the American Society of Clinical Oncology (ASCO), that came to a close yesterday in…
08 Jun 2017
Last month´s two-day exchange and debate on reversing cancer drug resistance: the Biocat and Obra Social “la Caixa” B-Debate 07 – 08 April 2016
Co-Organized by the Catalan Institute of Oncology (ICO), the Program Against Therapeutic Resistance (ProCURE), and Vall d´Hebron Institute of Oncology…
18 May 2016
Latest ESMO study reveals alarming disparities in availability and accessibility of anti-cancer therapies across Europe
Recently published as a Special Article in the flagship journal of the European Society of Medical Oncology (ESMO), Annals of…
05 Aug 2016
The BBVA Foundation Tumor Biomarkers Research Program unites Massachusetts General Hospital Cancer Center and Vall d’Hebron Institute of Oncology in the search for personalized cancer therapies
The BBVA Foundation Tumor Biomarkers Research Program unites Massachusetts General Hospital Cancer Center and Vall d’Hebron Institute of Oncology in the search for personalized cancer therapies
16 Nov 2011
Sea sponge drug could boost advanced breast cancer survival by five extra months
Promising results from the study Efficacy of eribulin in patients with metastatic breast cancer (MBC): a pooled analysis by HER2…
07 Nov 2014
Multi-center study led by CIC bioGUNE reveals metabolic pathway implicated in prostate cancer growth
Published in Nature journal today, a multi-center study led by CIC bioGUNE´s Arkaitz Carracedo, Ikerbasque Research Professor, Associate Professor at the…
29 Jun 2017
A new treatment improves the survival rates of patients with metastatic breast cancer
• The findings of the study, headed by the Breast Cancer Group at the VALL D’HEBRON ONCOLOGY INSTITUTE (VHIO) in Barcelona, present a new treatment option for patients with metastatic breast cancer.
• Eribulin is the first drug in the last 10 years to have an impact on metastatic breast cancer survival rates without having to be combined.
• The drug improves survival rates by 20% and has a very good toxicity profile compared to other chemotherapy drugs.
• The objective of the Phase III clinical trial was to identify the efficacy of a new treatment strategy for metastatic breast cancer.
03 Mar 2011
FDA Allows WIN Consortium to Proceed with Targeted Tri-Therapy Clinical Trial in First Line Treatment of Metastatic Non Small Cell Lung Cancer
Source: WIN Consortium VILLEJUIF, France–(BUSINESS WIRE)– WIN Consortium (WIN) received the US Food and Drug Administration (FDA)’s approval to start…
09 Aug 2017
VHIO´s Joaquín Arribas appointed as Scientific Director of Oncology for national virtual hub of biomedical excellence
Officially announced yesterday, Joaquín Arribas, Director of Preclinical Research at VHIO, Principal Investigator of VHIO´s Growth Factors Group, and ICREA…
14 Dec 2016
Immunotherapy shown to be effective against metastatic bladder cancer
Clinical research carried out as a phase I study shows that immunotherapy is safe and effective in reducing the size…
27 Nov 2014
An independent nationwide evaluation ranks Vall d´Hebron´s Medical Oncology Service top of the leaderboard for second consecutive year
Barcelona, 18 November 2015.-According to a second independent, annual benchmark evaluation of the Spanish healthcare sector, Monitor de Reputación Sanitaria…
18 Nov 2015
The molecular mechanism behind elevated TGF-beta levels in the most aggressive brain tumor revealed
Latest research from the Vall d’Hebron Institute of Oncology (VHIO) in Barcelona, recently published in the prestigious journal Cancer Discovery,…
08 Sep 2014
ICREA: promoting latest discovery to better elucidate cancer evolution and tumor heterogeneity
Considering cancer from an evolutionary perspective in order to better understand its vast complexity and clonal dynamics is undoubtedly opening…
09 Mar 2017
